GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC

Opinion
Video

Panelists discuss how the 24-month data from the GALAXY study presented at the European Society for Medical Oncology (ESMO) 2024 meeting underscore the importance of minimal residual disease (MRD) status and circulating tumor DNA (ctDNA) clearance as key prognostic and predictive factors in colorectal cancer (CRC) management.

Recent Videos
Related Content